Why Türkiye for Clinical Research?

As global clinical development demands faster recruitment, high data quality, and cost efficiency, Turkey has emerged as a premier hub for Phase I–IV clinical trials. Positioned strategically at the crossroads of Europe and Asia, Turkey offers a dynamic combination of modern healthcare infrastructure, highly motivated investigators, an immense patient population, and strong regulatory alignment with global standards.

1. Demographics & Patient Access

• 85+ Million Population: Turkey offers access to a large, ethnically diverse, and concentrated population, providing a rich foundation for trial participation across diverse genetic backgrounds.
• High Concentration of Naïve Patients: A significant proportion of patients in major metropolitan areas are treatment-naïve for emerging therapies, accelerating trial startup and enrollment velocity.
• Urbanized Healthcare Delivery: Over 90% of the population resides in or near major urban centers with direct access to tertiary care and university medical campuses, minimizing patient drop-off and travel barriers.

2. World-Class Healthcare Infrastructure

• State-of-the-Art City Hospitals (Şehir Hastaneleri): Turkey’s massive infrastructure investment has established mega-hospital complexes nationwide equipped with cutting-edge diagnostic tools, modern ICU units, and specialized clinical research departments.
• Centralized Electronic Health Records (EHR): Turkey’s national e-Health system (e-Nabız) enables digitized patient tracking, rapid pre-screening, and seamless audit-ready trial documentation.
• Accredited Facilities: Major university and research hospitals hold international accreditations, ensuring high operational compliance across all study phases.

3. Motivated Investigators & Specialized Sites

• GCP-Trained Key Opinion Leaders (KOLs): Turkish Principal Investigators are globally recognized experts across various therapeutic fields, heavily involved in international research networks and dedicated to high protocol adherence.
• Dedicated Clinical Research Units: Specialized research units within leading academic medical centers feature dedicated clinical research coordinators (CRCs), pharmacy facilities, sub-zero sample storage, and certified central lab partnerships.
• High Site Retention & Compliance: Strong patient-physician relationships in Turkish healthcare culture contribute to industry-leading patient retention rates and high visit compliance.

4. Streamlined Regulatory Environment

• Centralized Regulatory Authority: All clinical trial applications are managed directly through the Turkish Medicines and Medical Devices Agency (TİTCK), officially a part of Ministry of Health (MoH), using its centralized online portal. This fully digital submission process ensures transparent tracking, faster communication, and centralized administrative oversight.
• Single Central Ethics Committee & Parallel Submission: Approval requires submission to only one Central Ethics Committee (associated with the chosen coordinating site) for country-wide authorization, eliminating individual local site EC reviews. Furthermore, CEC and TİTCK submissions can be run in parallel, drastically reducing administrative overhead and accelerating overall study startup timelines across all participating sites.
• Harmonized with EU & ICH-GCP: Turkey’s regulatory framework closely aligns with EU Clinical Trial Directives and ICH-GCP guidelines, ensuring that study data is fully accepted by major global agencies including the FDA and EMA.
• Predictable Approval Timelines: Ethics Committee (EC) and Ministry of Health approvals run on standardized, predictable cycles, helping sponsors meet tight study launch milestones.

5. Favorable Patient-to-Trial Ratio

• Low Competition Across Indications: Compared to saturated Western European and North American trial markets, Turkey features a significantly lower ratio of active trials per eligible patient population.

• Broad Therapeutic Strength: High disease prevalence and centralized referral networks drive efficient recruitment in key therapeutic areas:
• • Oncology & Hematology
  • Rare & Genetic Diseases
  • Cardiovascular & Metabolic Disorders
  • Central Nervous System (CNS) & Neurology
  • Immunology & Rheumatology
  • Infectious Diseases

6. Financial & Strategic Advantages

• Significant Cost Efficiency: Operational, investigator, and site costs in Turkey are substantially lower than in Western Europe and the US, allowing sponsors to maximize budget efficiency without sacrificing data quality.
• Logistical Synergy & Central Location: Located in between three continents, with direct flights connecting Istanbul to almost every major city in Europe, the Middle East, and North America, Turkey offers efficient drug shipment, biological sample transport, and seamless site monitoring.

Ready to Expand Your Clinical Trial to Turkey?

• Partnering with local operational experts ensures smooth regulatory navigation, rapid site activation, and reliable trial execution from feasibility to study closeout.
• To request a protocol feasibility assessment or submit a Request for Proposal (RFP), please contact our business development team directly via our contact form. We typically deliver preliminary country-level feasibility feedback within 3-4 business days. For business inquiries, you can also e-mail our clinical team at clinical@elevate.com.tr.